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Background: It remains unknown if later life breast cancer risk as determined by reproductive history ismediated
by postmenopausal breast density and/or sex steroid levels.
Methods: Increased breast density is a strong surrogate for future breast cancer risk. A cross-sectional studywith a
longitudinal follow-up for breast health outcomes evaluated women without breast cancer (n= 1023; 682 =
parous), drawn from a high risk postmenopausal population, with questionnaire- reported reproductive histo-
ries. The questionnaire was linked to prospective screening mammogram breast density measurements, and sa-
liva biospecimens that were used to assess sex steroid hormone levels.
Results: Expected age- and postmenopause- related declines in salivary estradiol (E), progesterone (P), dehydro-
epiandrosterone (DHEA) and testosterone (T) levels were observed. This was most pronounced for DHEA and T,
whichwere also the only postmenopausal hormone levels signiﬁcantly associatedwith any reproductive charac-
teristics: parity and breast feeding for DHEA, and age-at-ﬁrst birth for T. Postmenopausal breast density was bor-
derline signiﬁcantly lower with parity and higher body mass index (BMI). After multivariate analysis, T was the
only hormone level to retain any association (negative, p b 0.05) with breast density.
Conclusions and general signiﬁcance:While reproductive characteristics, in particular parity, generally demon-
strated independent associationswith postmenopausal breast density and E, P and DHEA levels, T levels showed
concordant inverse associations with age-at-ﬁrst birth and breast density. These ﬁndings suggest that reproduc-
tive effects and later life salivary sex steroid hormone levels may have independent effects on later life breast
density and cancer risk.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Reproductive history, and in particular age at ﬁrst birth, has been
repeatedly demonstrated to be associated with breast cancer risk [1].
However, there is a lack of understanding of the mechanisms by
which pregnancy confers changes in breast cancer risk, thus limiting
the extent to which these ﬁndings can be translated into interventions
for prevention. Two mechanistic hypotheses include: i. Persistent
changes in the hormonal milieu, and ii. Permanent morphological and
gene expression changes imprinted by pregnancy-induced mammary
gland differentiation. There is support for each of these hypotheses
from epidemiological [1,2], observational and intervention researchrtment of Health and Human
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. This is an open access article under[3], and animal studies [4–6]. Either of these hypotheses may be mani-
fested by changes in later life breast density.In addition to age-at-ﬁrst
full-term birth, epidemiological evidence supports an association be-
tween breast cancer risk and prior pregnancy characteristics including
pre-term birth, preeclampsia, multi-fetal gestation and small placental
weight [1,7,8]. Mammographic density has a strong relationship to
breast cancer risk [9,10]. Reproductive history has also been reported
to be related to breast density, with increased density associated with
pre-term birth, nulliparity, and late age-at-ﬁrst birth [8,11–13]. These
ﬁndings appear strongest for ﬁrst pregnancies, although many remain
controversial [10]. Conﬁrmation of these ﬁndings could provide evi-
dence that pregnancy characteristics inﬂuence breast cancer risk
through hormonally mediated changes in the structure of the breast.
There is however, conﬂicting evidence for a link between pregnancy,
hormone levels and breast cancer. A secondary analysis of the Nurses
Health Study showed a relationship between postmenopausal serumthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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studies have shown no association between circulating sex hor-
mones and parity [15–17]. In postmenopausal women, circulating
sex steroid hormone levels are strongly associated with breast can-
cer risk [16,17], but any association of these hormone levels with
breast density remains uncertain.
To address the question of whether early life reproductive factors,
known to be associated with later life breast cancer risk, either mediate
or moderate postmenopausal breast density and/or salivary sex steroid
levels, we performed a cross-sectional analysis drawn from the larger
MarinWomen's Study (MWS). Postmenopausal womenwithout breast
cancer (n= 1,023; 682 = parous), and their self reported lifestyle and
reproductive characteristics (including ﬁrst pregnancy events), were
examined along with screening mammogram breast density measure-
ments. Self obtained saliva biospecimenswere used to assess sex steroid
hormone levels (estradiol, progesterone, dehydroepiandrosterone, tes-
tosterone). Saliva measurements reﬂect (but are not necessarily equal
to) free plasma or serum concentrations of various steroidal hormones,
certain growth factors, and many drugs if they are capable of being
transferred by either intracellular (e.g. diffusion) or extracellular (e.g.
ultraﬁltration) mechanisms. Thus, numerous studies of saliva-based
diagnostics have established that clinically relevant analyte concentra-
tions in saliva correlated with tissue ﬂuid levels and can be used either
for drug monitoring or to evaluate endocrine function, in particular
circulating (unbound) levels of lipid-soluble steroids like cortisol,
aldosterone, dehydroepiandrosterone, testosterone, progesterone, and
estradiol [18].2. Materials and methods
2.1. Marin Women's Study (MWS) population and measurements
This study was conducted within the context of the MWS. Marin
residents were recruited through mammography facilities in Marin
County and San Francisco which are included in the San Francisco
Mammography Registry (SFMR), one of the seven registries compris-
ing the National Cancer Institute Breast Cancer Surveillance Consor-
tium. This study was approved by the Marin General Hospital and
Kaiser Permanente Northern California Institutional Review Boards,
and all participants provided informed consent to fully participate
in the study. Primary data collection in the MWS included self-
reported information via a detailed questionnaire and saliva samples
collected from consenting women. Secondary data were obtained by
linkage with the SFMR on volumetric compositional breast density
and breast cancer case status, as well as family history, weight and
height. The MWS has been previously described and characterized
[12]. To date, 13,365 women have been enrolled in the MWS and
completed the questionnaire. Of these, about 85% also consented to
saliva donation, and 70% completed the process of donation as
instructed and produced biobanked specimens.2.2. Questionnaire components
The questionnaire was ﬁlled out by all consenting women as their
entry point into the MWS. It included detailed questions about repro-
ductive history, life course socioeconomic data, alcohol use, andmedica-
tion use, including NSAIDs, which can affect endogenous levels of
steroids like DHEA [19]. Additional questions about well-established
risk factors included exogenous hormone exposures, and history of pre-
vious breast procedures. Reproductive factors included age atmenarche
andmenopause, and speciﬁc pregnancy-related questions included par-
ity, age-at-ﬁrst birth, infertility and treatment for infertility, duration of
breast feeding, birth weight of children, preterm birth, pregnancy
weight gain, and pregnancy related hypertension.2.3. Calibrated mammographic density
One of the novel features of this study is the measure of breast den-
sity as % ﬁbroglandular volume (%FGV), by themethod of single-energy
X-ray absorptiometry (SXA). Thismethod uses a calibration phantom of
the same thickness as the compressed breast, circumventing some of
the problems associated with other breast density measures, such as
subjectivity and a lack of absolute reference standards [20]. This study
used the ﬁrst generation calibration phantom (Gamma). Initial results
on over 8600 women showed that SXA is precise and accurate when
using reference phantoms, and inversely correlated with age, BMI and
menopausal status; it is also positively associated with breast cancer
risk [21,22]. %FGV data were obtained from the SFMR through a cooper-
ative agreement upon linkage to MWS data for all consenting women.
2.4. Saliva collection and steroid hormone assay
Saliva samples were collected to assess steroid hormone levels, as
saliva testing represents a cost effective approach to screening large
populations [18]. Sex steroids were measured from cryobanked saliva
after precipitating out all cell and particulate components. At the time
of entry into the MWS, women were asked on the questionnaire if
they were willing to donate a saliva specimen. Those who consented
were sent a kit in the mail. Returned specimens were bar coded, logged
and cryobanked. In total, 8598 saliva samples have been processed.
Processed supernatants were sent to Aeron Biotechnology, Inc. (San
Leandro, CA) for radioimmunoassay (RIA) of dehydroepiandrosterone
(DHEA), estradiol (E), progesterone (P) and testosterone (T). The entire
MWS sample set submitted for analysis of these four steroid hor-
mones (n = 1784) were compared to results from an independent
contemporary cohort of female samples randomly submitted for
commercial analysis, to conﬁrm expected age-speciﬁc changes in
the hormone levels (Fig. 1). Criteria for inclusion in the MWS saliva
analysis required submission of a non-bloody early morning saliva
sample of N3 ml volume, following at least 8 h of fasting. Samples from
post-menopausal women required attesting to an absence of menses
for at least one year.
2.5. Statistical analyses
The analytic sample comprised 1023 postmenopausal women not
taking exogenous hormones who had an analyzable saliva sample for
hormone levels and questionnaire data on the variables included in
the model. Distributions of the salivary hormone levels were examined
against a reference range of postmenopausal women to verify that
levels were consistent with the known ranges for this population. Mul-
tivariable linear regression analyses were constructed using Stata 11.2
(StataCorp. 2009. Stata Statistical Software: Release 11. College Station,
TX: StataCorp LP) to examine the associations between salivary hor-
mone levels, %FGV and reproductive factors, controlling for relevant
confounders. The models employed robust regression using iteratively
reweighted least squares tominimize the effects of outliers. To examine
the association between salivary hormone levels and known or
suspected confounders, a separatemodel was constructed for each hor-
mone and included a base set of confounding variables. The base set of
variables included continuous current age, BMI, hours ofweeklymoder-
ate or vigorous exercise, number of alcoholic drinks consumed per day,
parity, and age at menopause, as well as race (Black, White, Asian, His-
panic, Other), education (high school or less, some college, college
degree or higher), use of complementary and alternative medicines
(CAMS—or natural nonprescription hormone medications) (yes/no),
and age atmenarche (10 or younger, 11–14, 15+). Onemodel was con-
structed for the entire population examining the reproductive factors of
parity, age atmenarche, and age atmenopause. Anothermodel restrict-
ed to parouswomenwas examined using awider range of reproductive
factors related to the ﬁrst pregnancy including weeks gestation, high
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Fig. 1.Age-speciﬁc salivary sex steroid hormone levels in theMarinWomen's Study (MWS) cohort. Earlymorning saliva samples (n=1784) collected, cryobanked and processed in com-
pliancewith theMWSprotocol, as described inMethods, were analyzed by RIA for levels of estradiol (E), progesterone (P), testosterone (T) and dehydroepiandrosterone (DHEA). The age
(decade) distribution of log-transformed hormone values is box plotted as shown; and the age-speciﬁc sex steroid hormone levels from theMWS samples are shown in relation to a geo-
graphically independent, contemporary cohort of US females (not part of the MWS) who provided saliva samples by the same collection protocol, identically processed and analyzed
(Aeron Biotechnology). Age-speciﬁc changes in hormone levels were tested for signiﬁcance (p-values) by analysis of trends. A subset of these MWS saliva samples collected from post-
menopausal women (n= 1023) were used for the study comparison with reproductive characteristics and postmenopausal breast density.
Table 1
Covariate distribution (n= 1023).
Characteristic Mean (SD)
%FGV 28.49 (16.59)
Parity 1.63 (1.29)
Number of alcoholic drinks per day 0.91 (.99)
BMI 24.76 (4.69)
Hours of strenuous and moderate exercise per week 8.99 (3.94)
Age of menopause (among menopausal women) 50.81 (5.74)
Current age (years) 62.80 (8.02)
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weight, and duration of breast feeding. Prior to regression, hormone
levels were log transformed and % FGV was square root transformed
to normalize the distribution. Women were excluded from all analyses
if they had a history of breast cancer, if their ﬁrst birthwasmultiple ges-
tation, if they had used antiestrogens in the last ﬁve years, if they had a
history of ovariectomy, or if any of the variable data was missing from
the questionnaire. In the model where %FGV was the dependent vari-
able, we also controlled for family history of breast cancer (ﬁrst degree
relative), hormone use near the time of the mammogram, and a mea-
sure of the number of days between saliva donation and %FGVmeasure-
ment. Models in which one of the four assayed hormone levels was the
dependent variable included the base set of confounding variables plus
batch, number of hours fasting, and time of saliva donation. Given the
numerous comparisons being made, borderline signiﬁcant ﬁndings
are not highlighted in the results section.Characteristic Percent
Taking CAMS 4.50%
Smoking
Never 46.92%
Current 3.03%
Former 50.05%
Education
HS or less 4.69%
Some college 26.20%
College or more 69.11%
Race
White 93.16%
Black 0.39%
Asian 2.74%
Other 1.76%
Hispanic 1.96%3. Results
3.1. The Marin Women's Study (MWS) biospecimens and saliva steroid
levels
The results of the 1784 saliva supernatants submitted for commer-
cial analysis of steroid hormone levels are presented in Fig. 1. The age
speciﬁc hormone levels of theMWS cohort appear generally concordant
with those of an independent and contemporary cohort of women, in
which expected age and postmenopausal hormonal declines are appar-
ent. In both these female cohorts, the most signiﬁcant age-related hor-
monal decreases were noted in DHEA and testosterone levels (Fig. 1).
Many of the elevated estradiol and progesterone levels in MWS studysubjects over age 50 illustrated in this ﬁgure reﬂected their reported
use of HRT; these study samples were excluded from the subsequent
analysis of postmenopausal subjects, resulting in a ﬁnal postmenopaus-
al set of 1023 saliva samples for hormone analysis.
Table 3
Mean levels of salivary hormones (postmenopausal women, n= 1023).
Geometric means
(pg/ml)
Reference range (postmenopausal
women)
DHEA 109.56 33–200 (age-speciﬁc)
Estradiol 0.77 b1.5
Progesterone 20.32 b50
Testosterone 19.87 11–35 (age-speciﬁc)
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ty, reproductive parameters, hormone levels)
The study sample (n = 1023) represents the subset of postmeno-
pausal study subjects submitting saliva samples eligible for hormone
analysis (Table 1). The mean %FGV in the analysis population was
28.49. The majority of the population is white, has a college degree, a
normal BMI, and is on average 11.8 years postmenopausal.
Table 2 presents the distribution of reproductive characteristics for
this postmenopausal MWS cohort. Nearly one quarter (24.8%) of
women had a ﬁrst birth at age 30 years or older. Pregnancy induced hy-
pertension was reported by 4.47% of the population, and high and low
birth weight were reported by 9.14% and 5.49% of the cohort, respec-
tively. Ninety-two percent (92%) of the respondents reported that
their ﬁrst birth was full term, with a mean 29.65 pound weight gain.
On average, respondents reported 6.34 months of breastfeeding after
this ﬁrst birth.
The distribution of hormone levels (geometric means) is presented
in Table 3. Mean levels for the analysis populations were within the ref-
erence range for postmenopausal women for DHEA, estradiol, proges-
terone and testosterone (109.56, 0.77, 20.32, and 19.87, respectively).
3.3. Multivariate analyses
A multivariate model examining the reproductive factors of parity,
age at menarche and age at menopause is presented in Table 4. In this
set of models, the only association between one of the hormone levels
and parity was the positive association with DHEA (p = 0.01). Age
was signiﬁcantly negatively associated with levels of DHEA and testos-
terone (p b 0.001). BMI was signiﬁcantly associated with DHEA (p =
0.002), as was weekly exercise (p = 0.04) and current smoking (p =
0.01). BMI was also signiﬁcantly associated with estradiol (p= 0.001).
Use of complementary and alternative medicine (CAMS) was signiﬁ-
cantly associated with progesterone levels (p= 0.04).
Table 5 shows associations between hormone levels and charac-
teristics of ﬁrst birth in the postmenopausal subset of parous
women (n = 682). When controlling for all other factors in the
model, including levels of the three other study hormones, breastTable 2
Distribution of reproductive characteristics (n= 1023).
Characteristic Percent
Age at ﬁrst birth
Nulligravid 16.42%
Nulliparous 10.75%
b20 2.93%
20–29 45.06%
30–34 15.25%
35+ 9.58%
Menarche
10 or younger 4.99%
11–14 86.61%
15+ 8.41%
First pregnancy characteristic in parous women Percent
Birthweight
Low 5.49%
High 9.14%
Normal 85.37%
Pregnancy high blood pressure (%) 4.47%
Weeks gestation
38+ 92.27%
36–37 6.51%
≤35 1.22%
First pregnancy characteristic in parous women Mean (SD)
Pregnancy weight gain (pounds) 29.65 (11.70)
Months of breastfeeding (ﬁrst child) 6.34 (7.03)feeding was signiﬁcantly positively associated with DHEA levels
(p = 0.04). No other reproductive factors were signiﬁcantly related
to DHEA. The proportion of the variability in DHEA explained by
this model was 38% due in large part to the inclusion of estradiol,
progesterone and testosterone as variables; an analogous model
that did not include simultaneous control for the other three hor-
mones had an R squared value of 10% (data not shown). There
were no signiﬁcant associations between reproductive factors and
estradiol or progesterone. The model for estradiol explained 19% of
the variability in estradiol, while the model for progesterone explained
20% of the variability in progesterone. Thirty nine percent (39%) of
the variability in testosterone was explained by this model.
The results of the multivariate regression model of hormone levels
on %FGV are shown in Table 6. The only hormone signiﬁcantly associat-
ed with %FGV was testosterone, which showed a negative association
with %FGV (p= 0.04). BMI was also signiﬁcantly, negatively associated
with %FGV (p b 0.001). Asianwomen had signiﬁcantly higher %FGV than
white women (p = 0.02) even after control for the other model
variables.
4. Discussion
4.1. Parity, postmenopausal steroid hormone associations, and breast
cancer risk
In this study population of 1023 postmenopausal women in the
MWS, parity was positively associated with only DHEA. No other sali-
vary hormones were signiﬁcantly related to parity in this group.
When these associations are taken without adjusting for other hor-
mones, it is hard to determine the extent to which postmenopausal
DHEA inﬂuences breast cancer risk in this population. Postmenopausal
testosterone levels have clearly been linked to an increased risk of
developing hormone receptor positive breast cancer [23], but such evi-
dence relating to DHEA has not been as convincing. Earlier prospective
case control studies have shown that postmenopausal DHEA levels cor-
relate positively with breast cancer risk [24]. However, in a more recent
analysis from the Nurses' Health Study of endogenous hormone levels
and postmenopausal breast cancer risk wherein signiﬁcantly positive
associations with risk were shown for estradiol and testosterone levels
(RR = 1.3 and 1.29, respectively), the weaker increase in breast cancer
risk seen with sulfated DHEA (RR= 1.15) became non-signiﬁcant upon
stepwise regression analysis [23]. As a metabolic precursor to both
androgens and estrogens, DHEA is produced in the adrenals, gonads
and brain; and evenmuch later in life DHEA remains themost abundant
of all circulating sex steroids, as shown in the current study (Table 3).
Although a weak partial agonist of the androgen receptor (AR) and
both forms of estrogen receptor (ERalpha and ERbeta), the higher circu-
lating levels of DHEA over E2 and T do not come close to compensating
for its much weaker AR and ER binding afﬁnities. Therefore, consistent
with the current controversy over whether DHEA enhances or reduces
the risk of breast (or prostate) cancer, not to mention the fact that sex
steroid receptor-independent effects of DHEA have also been reported
that could alter mammary gland susceptibility to tumorigenesis [25],
it is not possible to conclude that our observed association between par-
ity and DHEA is at all linked to postmenopausal breast cancer risk. Of
note, DHEA levels can also be induced by vigorous exercise and caloric
Table 5
Linear regression model: salivary hormone levels in parous postmenopausal MWS women with hormone measurement and model variables (n= 682).
Log DHEA Log estradiol Log progesterone Log testosterone
Beta coefﬁcient (95% CI) Beta coefﬁcient (95% CI) Beta coefﬁcient (95% CI) Beta coefﬁcient (95% CI)
Reproductive factors
Parity (number: 1–5) .04 (− .01, .08) .01 (− .01, .04) .00004 (− .04, .04) − .003 (− .04, .03)
Weeks gestation (versus 38+ weeks)
36–37 weeks .09 (− .08, .26) − .03 (− .12, .07) − .02 (− .15, .11) − .04 (− .16, .08)
b35 weeks .04 (− .31, .38) .04 (− .16, .24) .001 (− .27, .27) .10 (− .15, .34)
High blood pressure (vs. no) − .12 (− .32, .08) − .03 (− .14, .09) .10 (− .05, .26) .01 (− .13, .16)
Gestational weight gain (lbs) .0005 (− .003, .004) − .002 (− .004, .001) .001 (− .002, .004) − .0001 (− .003, .003)
Age at ﬁrst birth (vs. b20)
20–29 .14 (− .07, .36) .02 (− .11, .14) − .07 (− .23, .10) − .14 (− .29, .02)⁎⁎
30–34 .12 (− .11, .35) .02 (− .11, .16) − .07 (− .25, .11) − .09 (− .25, .07)
35+ .12 (− .12, .37) − .01 (− .15, .13) − .05 (− .24, .14) − .08 (− .25, .10)
Birthweight (vs. normal)
Low .09 (− .09, .28) − .03 (− .13, .08) .02 (− .13, .16) − .09 (− .23, .04)
High .02 (− .12, .16) .02 (− .06, .11) .08 (− .03, .19) − .02 (− .12, .08)
Breastfeeding (months) .01 (.0003, .01)⁎ .0004 (− .003, .004) − .003 (− .01, .002) − .0004 (− .005, .004)
Menarche (vs. ≤10)
11–14 .01 (− .18, .20) .02 (− .09, .13) − .02 (− .17, .13) .09 (− .04, .23)
15+ − .03 (− .27, .20) − .03 (− .17, .10) .06 (− .12, .25) .07 (− .09, .24)
Other factors
Age (years) − .02 (− .03,− .01)⁎ − .0004 (− .004, .003) .01 (.004, .01)⁎ .004 (− .0005, .01)⁎⁎
CAMS use − .11 (− .32, .10) − .02 (− .14, .11) .20 (.03, .36)⁎ − .18 (− .33,− .03)⁎
BMI .005 (− .01, .01) .004 (− .002, .01) − .01 (− .02,− .01)⁎ .01 (.002, .02)⁎
Alcohol consumption .03 (− .01, .07) − .01 (− .04, .02) − .01 (− .04, .03) .02 (− .01, .06)
Weekly exercise .01 (− .003, .02) − .002 (− .01, .004) .00003 (− .01, .01) .004 (− .004, .01)
Smoking (versus never)
Current .23 (− .01, .47)⁎⁎ .04 (− .10, .18) − .21 (− .40,− .02)⁎ − .001 (− .17, .17)
Former − .05 (− .13, .04) .03 (− .02, .08) .01 (− .06, .08) .002 (− .06, .06)
Race (vs white)
Black .86 (− .17, 1.88) − .01 (− .61, .60) − .28 (−1.09, .53) − .41 (−1.14, .33)
Asian − .09 (− .32, .15) − .001 (− .14, .14) .02 (− .16, .21) .0002 (− .17, .17)
Other − .08 (− .40, .24) .04 (− .14, .23) .14 (− .11, .39) − .12 (− .34, .11)
Hispanic − .13 (− .40, .15) .08 (− .08, .25) .21 (− .01, .42)⁎⁎ − .08 (− .28, .11)
Education (versus HS or less)
Some college .05 (− .15, .24) .01 (− .10, .13) − .14 (− .29, .01)⁎⁎ − .03 (− .16, .11)
College graduate .01 (− .18, .20) − .01 (− .12, .10) − .12 (− .27, .03) − .02 (− .15, .12)
R2 .38 .19 .20 .39
Controlled for batch, hours fasting, and time donated. Includes simultaneous control for other hormones.
⁎⁎ Denotes borderline signiﬁcance (p b 0.1).
⁎ Denotes statistical signiﬁcance (p b 0.05).
Table 4
Linear regression model: salivary hormone levels in postmenopausal MWS women with hormone measurement and model variables (n= 1023).
Log DHEA Log estradiol Log progesterone Log testosterone
Beta coefﬁcient (95% CI) Beta coefﬁcient (95% CI) Beta coefﬁcient (95% CI) Beta coefﬁcient (95% CI)
Reproductive factors
Parity (0–5) .04 (.01, .07)⁎ .01 (− .01, .02) − .001 (− .02, .02) .01 (− .02, .03)
Menarche (vs. ≤10)
11–14 .07 (− .11, .26) − .0002 (− .10, .10) .07 (− .06, .20) .10 (− .04, .24)
15+ .02 (− .06, .10) − .04 (− .17, .08) .11 (− .05, .27) .05 (− .12, .23)
Age of menopause .0004 (− .01, .01) − .001 (− .004, .003) − .002 (− .01, .003) .004 (− .002, .01)
Other factors
Age (years) − .02 (− .03,− .02)⁎ − .001 (− .004, .002) .001 (− .003, .004) − .01 (− .01,− .01)⁎
CAMS use .04 (− .16, .23) .04 (− .07, .14) .14 (.003, .28)⁎ .05 (− .10, .20)
BMI .01 (.005, .02)⁎ .01 (− .003, .01)⁎ − .01 (− .01, .001) .02 (.01, .02)
Alcohol consumption .02 (− .02, .06) .01 (− .02, .03) − .03 (− .06, .002)⁎⁎ .03 (− .002, .06)⁎⁎
Weekly exercise .01 (.001, .02)⁎ .001 (− .004, .01) − .001 (− .01, .01) .003 (− .005, .01)
Smoking (versus never)
Current .31 (.07, .55)⁎ − .10 (− .23, .03) .05 (− .12, .21) .11 (− .08, .29)
Former .02 (− .06, .10) .01 (− .03, .06) .02 (− .04, .08) .04 (− .02, .11)
Race (vs white)
Black .09 (− .55, .73) − .22 (− .57, .12) .20 (− .25, .65) − .18 (− .67, .31)
Asian − .10 (− .34, .15) .02 (− .12, .15) − .04 (− .22, .13) .01 (− .18, .20)
Other − .16 (− .46, .14) − .02 (− .18, .15) .01 (− .21, .22) − .20 (− .43, .03)⁎⁎
Hispanic − .22 (− .51, .07) .01 (− .15, .16) .10 (− .11, .31) − .16 (− .38, .07)
Education (versus HS or less)
Some college .05 (− .15, .25) .02 (− .09, .13) − .12 (− .26, .03) − .05 (− .21, .10)
College graduate .02 (− .17, .21) .01 (− .09, .12) − .11 (− .24, .03) − .05 (− .20, .10)
R2 .09 .04 .02 .04
Controlled for batch, hours fasting, and time donated. Models do not include simultaneous control for other three hormones.
⁎⁎ Denotes borderline signiﬁcance (p b 0.1).
⁎ Denotes statistical signiﬁcance (p b 0.05).
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194 M. Mockus et al. / BBA Clinical 3 (2015) 189–195restriction sufﬁcient to achieve a lean body mass. Since vigorous exer-
cise and low BMI are clearly associated with decreased postmenopausal
breast cancer risk, higher DHEA levels in the MWS population could
actually correlate with lower breast cancer risk by acting as a surrogate
biomarker for risk-reducing exercise and lower BMI in this population.
4.2. First pregnancy association with postmenopausal hormone levels and
mammographic density
DHEAwas signiﬁcantly associatedwith breastfeeding among parous
women, but among this group of parous women, the number of births
(parity) was not signiﬁcantly associated with DHEA. The only other
association between a reproductive factor and hormone level among
parous women was the borderline signiﬁcant negative association be-
tween testosterone and age-at-ﬁrst birth between ages 20 and 29 (com-
pared to birth before age 20). The postmenopausal hormone levels best
associated with pregnancy characteristics (DHEA, testosterone) did not
show comparable associations with postmenopausal mammographic
density. This observation may mean that pregnancy itself induces
early, persistent, and protective morphologic changes in the breast
reﬂected in postmenopausal breast density, but by mechanisms other
than long lived hormonal changes. In this fashion, ﬁrst pregnancy char-
acteristics and postmenopausal hormone levels would be expected to
inﬂuence breast cancer risk independently.
4.3. Reproductive characteristics and postmenopausal mammographic
density
Given the strong association between breast cancer risk and mam-
mographic density, whether measured by conventional BIRADS (Breast
Imaging Reporting andData system) classiﬁcation ormoremodern SXATable 6
Linear regression model: %FGV in parous postmenopausal women (n= 636).
%FGV
Beta coefﬁcient (95% CI)
Reproductive factors
Parity (number: 0–5) − .07 (− .15,.01)⁎⁎
Menarche (vs. ≤10)
11–14 − .28 (− .73,.17)
15+ − .18 (− .72,.36)
Age of menopause .01 (− .01,.02)
Salivary hormone levels
DHEA .08 (− .08,.24)
Estradiol .09 (− .11,.29)
Progesterone .05 (− .10,.21)
Testosterone − .24 (− .45,− .03)⁎
Other factors
Age (years) − .01 (− .02,.01)
Hormone use at mammogram − .44 (− .95,.08)⁎⁎
BMI − .20 (− .22,− .18)⁎
Race (vs white)
Black .82 (− .52, 2.16)
Asian .62 (.10, 1.15)⁎
Other .27 (− .50, 1.05)
Hispanic .34 (− .28,.95)
Education (versus HS or less)
Some college − .09 (− .51,.34)
College graduate .01 (− .39, 41)
Weekly exercise − .003 (− .03,.02)
Alcohol consumption − .01 (− .10,.09)
Smoking (versus never)
Current − .06 (− .62,.49)
Former .03 (− .15,.22)
First degree relative with breast cancer .09 (− .13,.30)
R2 .33
⁎⁎ Denotes borderline signiﬁcance (p b 0.1).
⁎ Denotes statistical signiﬁcance (p b 0.05).quantitation of %FGV (as reported here), there has been continuing
interest in determining either correlative or causative links between
mammographic density and breast cancer risk although, to date, such
biological and genetic links remain largely unresolved [10]. Clear associ-
ations between changes in breast density and increasing age, higher
BMI, and exogenous hormone (e.g. combined E+ P replacement thera-
py) or anti-hormone (e.g. antiestrogen) use have spurred epidemiologic
studies seeking other associations consistentwith long term breast hor-
monal exposure. So far, meta analyses of these studies indicate no con-
sistent or signiﬁcant associations between postmenopausal breast
density and age-at-ﬁrst birth, breast feeding, or other reproductive
characteristics (after adjustment for age and BMI) other than parity
[10]. We observed that postmenopausal breast density was borderline
signiﬁcantly lower with parity (as well as with higher BMI), but not
with age at menarche, ﬁrst birth, or menopause. Hence, while our ﬁnd-
ings appear to be in complete agreementwithmany other epidemiolog-
ic studies, they do not implicate long term hormonal exposure and do
not shed any additional light on the partially protective effect of parity
on postmenopausal breast density.
4.4. Study strengths and weaknesses
This study has a number of important strengths, including a relative-
ly large sample size, a novelmeasure of breast density, and the availabil-
ity of information on a wide variety of reproductive characteristics and
other breast cancer risk factors.
The primary limitation in this study is the use of self-reported data
for reproductive history and early life risk factors such as age at menar-
che. Though it is possible that women may not accurately recall infor-
mation about their ﬁrst pregnancy, particularly if it occurred in the
distant past, we would expect that they would accurately recall the
major events including their age when they gave birth, and whether
they breast-fed. To the extent that misclassiﬁcation of exposures is
present, we expect that it would be nondifferential (i.e., not associated
with %FGV or salivary hormone levels), and would thus bias the results
toward the null. Another limitation is that, despite the fact that the over-
all sample size in this studywas large, the sample sizewas small for spe-
ciﬁc subgroup analyses. Studies with larger populations may be better
able to detect signiﬁcant associations between birth characteristics, hor-
mone levels, and breast density where they exist. Selection bias may be
present in the sample of patients providing saliva samples for the hor-
mone analyses; women who consented to donate saliva were signiﬁ-
cantly more likely to be of White Non-Hispanic race and to be of
higher socioeconomic status based on education and income, but were
not signiﬁcantly different in terms of family history of breast cancer or
current age. This selective participation would only be expected to
bias the results if the associations between birth characteristics, hor-
mone levels, and breast density differ by race or socioeconomic status.
While we do not anticipate that this would be the case, bias in the
results due to selective participation cannot be ruled out. This does,
however, limit the ability to generalize the ﬁndings here to a broader,
more racially diverse population. Finally, the analyses of birth character-
isticswere intentionally restricted to ﬁrst births, but it will be important
to determine whether the ﬁndings for ﬁrst birth characteristics hold for
all births or whether they are unique to the ﬁrst birth (e.g., whether
total duration of breast-feeding has the same associationwith hormone
levels as duration of breast-feeding after the ﬁrst birth).
5. Summary and conclusions
Expected age and postmenopause related declines in estradiol (E),
progesterone (P), dehyroepiandrosterone (DHEA) and testosterone
(T) levels were observed. DHEA and T were the only postmenopausal
hormone levels signiﬁcantly associated with any reproductive charac-
teristics: parity and breast feeding for DHEA, age-at-ﬁrst birth for T.
Postmenopausal breast density was borderline signiﬁcantly negatively
195M. Mockus et al. / BBA Clinical 3 (2015) 189–195associated with parity, and T was the only hormone level to retain any
association with %FGV in multivariable analysis (negative, p = 0.04).
These ﬁndings suggest that ﬁrst pregnancy effects on later life breast
density and cancer risk are not strictly mediated by later life sex steroid
hormone levels.
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